These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. Lubelski D; Abdullah KG; Weil RJ; Marko NF J Neurooncol; 2013 Dec; 115(3):317-22. PubMed ID: 24005770 [TBL] [Abstract][Full Text] [Related]
4. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Liu AK; Macy ME; Foreman NK Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1148-54. PubMed ID: 19857784 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837 [TBL] [Abstract][Full Text] [Related]
10. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Schmid BC; Oehler MK Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668 [TBL] [Abstract][Full Text] [Related]
12. The emerging role of anti-angiogenic therapy for malignant glioma. Reardon DA; Desjardins A; Rich JN; Vredenburgh JJ Curr Treat Options Oncol; 2008 Feb; 9(1):1-22. PubMed ID: 18256938 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for the treatment of high-grade glioma. Khasraw M; Simeonovic M; Grommes C Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836 [TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358 [TBL] [Abstract][Full Text] [Related]